11 Immunoglobulin-like beta-sandwich
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Alkaloids and derivatives | 18 | 5.3 | 3.41× | q < 0.0001 | |
| Organic oxygen compounds | 694 | 308.1 | 2.25× | q < 0.0001 | |
| Organic nitrogen compounds | 69 | 49.4 | 1.40× | q = 0.01 | |
| Homogeneous non-metal compounds | 379 | 333.0 | 1.14× | q = 8.8e-3 | |
| Homogeneous metal compounds | 784 | 759.4 | 1.03× | q = 0.28 | |
| Organosulfur compounds | 32 | 31.8 | 1.00× | q = 0.96 | |
| Benzenoids | 83 | 113.1 | 0.73× | q = 5.3e-3 | |
| Lipids and lipid-like molecules | 126 | 172.3 | 0.73× | q = 2.8e-4 | |
| Organic acids and derivatives | 153 | 239.4 | 0.64× | q < 0.0001 | |
| Phenylpropanoids and polyketides | 18 | 32.2 | 0.56× | q = 0.02 | |
| Hydrocarbons | 6 | 10.8 | 0.56× | q = 0.22 | |
| Organoheterocyclic compounds | 93 | 238.1 | 0.39× | q < 0.0001 | |
| Mixed metal/non-metal compounds | 9 | 32.5 | 0.28× | q < 0.0001 | |
| Nucleosides, nucleotides, and analogues | 21 | 427.6 | 0.05× | q < 0.0001 | |
| Organic salts | 3 | 1.6 | 1.86× | not tested | |
| Organohalogen compounds | 8 | 4.4 | 1.81× | not tested | |
| Organometallic compounds | 3 | 2.2 | 1.36× | not tested | |
| Lignans, neolignans and related compounds | 1 | 1.2 | 0.87× | not tested | |
| Miscellaneous inorganic compounds | 1 | 1.2 | 0.87× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00141 | NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 3,668 |
| DB02530 | ABU | GAMMA-AMINO-BUTANOIC ACID | 185 |
| DB00145 | GLY | GLYCINE | 159 |
| DB03345 | BME | BETA-MERCAPTOETHANOL | 146 |
| DB09459 | TLA | L(+)-TARTARIC ACID | 113 |
| DB18267 | HEM | PROTOPORPHYRIN IX CONTAINING FE | 99 |
| DB02777 | PLC | DIUNDECYL PHOSPHATIDYL CHOLINE | 92 |
| DB00184 | NCT | (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE | 67 |
| DB08231 | MYR | MYRISTIC ACID | 67 |
| DB03946 | DHB | 3,4-DIHYDROXYBENZOIC ACID | 62 |
| DB15954 | SY9 | STRYCHNINE | 60 |
| DB00171 | ATP | ADENOSINE-5'-TRIPHOSPHATE | 56 |
| DB01593 | — | — | 54 |
| DB14487 | — | — | 54 |
| DB04473 | FUC | alpha-L-fucopyranose | 53 |
| DB00898 | — | — | 52 |
| DB14533 | — | — | 42 |
| DB00151 | CYS | CYSTEINE | 41 |
| DB05137 | L0B | Alpha-Lobeline | 38 |
| DB12010 | — | — | 38 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 4,330 |
| CL | CHLORIDE ION | 2,192 |
| CAmetal | CALCIUM ION | 2,054 |
| ZNmetal | ZINC ION | 2,031 |
| NAmetal | SODIUM ION | 1,398 |
| CUmetal | COPPER (II) ION | 847 |
| MGmetal | MAGNESIUM ION | 675 |
| FEmetal | FE (III) ION | 310 |
| PLC | DIUNDECYL PHOSPHATIDYL CHOLINE | 281 |
| IOD | IODIDE ION | 251 |
| CDmetal | CADMIUM ION | 250 |
| MAN | alpha-D-mannopyranose | 211 |
| ABU | GAMMA-AMINO-BUTANOIC ACID | 182 |
| GLY | GLYCINE | 176 |
| Kmetal | POTASSIUM ION | 172 |
| NImetal | NICKEL (II) ION | 163 |
| BR | BROMIDE ION | 158 |
| BME | BETA-MERCAPTOETHANOL | 150 |
| TLA | L(+)-TARTARIC ACID | 125 |
| CU1metal | COPPER (I) ION | 122 |